Further to intimation dated November 05, 2024 and pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’), Lincoln Pharmaceuticals has informed that the Board of Directors of the Company at its meeting held today on Thursday, November 14, 2024, have considered and approved the un-audited financial results (standalone and consolidated) of the Company for the quarter and half year ended on September 30, 2024 along with the limited review report from auditors thereon. In terms of Regulation 47 of the Listing Regulations, the Company will publish an extract of un-audited consolidated financial results for the quarter and half year ended on September 30, 2024. The un-audited financial results (standalone and consolidated) will be available at Company's website at www.lincolnpharma.com. Further, it has enclosed the financial highlights for the aforesaid quarter. The Meeting of the Board of Directors of the Company commenced at 10:45 am and concluded at 12:10 pm.
The above information is a part of company’s filings submitted to BSE.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1777.65 |
Dr. Reddys Lab | 1194.55 |
Cipla | 1465.65 |
Lupin | 2043.30 |
Zydus Lifesciences | 944.25 |
View more.. |